Catumaxomab

Catumaxomab is a groundbreaking pharmaceutical ingredient, recognized as a unique trifunctional antibody designed to target and eliminate cancer cells. Developed as a bispecific antibody with an additional Fc region, its innovative structure allows it to simultaneously bind to three different cell types: tumor cells, T-lymphocytes (T-cells), and accessory immune cells. This distinct mechanism of action positions Catumaxomab as a pioneering agent in the field of cancer immunotherapy, specifically for treating certain types of malignant ascites.

What is Catumaxomab?

Catumaxomab, an International Nonproprietary Name (INN) also known as Removab®, is a unique rat-mouse hybrid trifunctional antibody. Unlike conventional antibodies, it's engineered to simultaneously bind to three distinct targets: EpCAM on tumor cells, CD3 on T-cells, and Fcγ receptors on accessory immune cells (e.g., macrophages, NK cells). This "trifunctional" design acts as a bridge, bringing immune effector cells into direct contact with tumor cells, thereby initiating a potent anti-tumor immune response. It represented a novel approach in cancer immunotherapy, particularly where conventional therapies had limited efficacy.

How Does it Work?

The mechanism of action of Catumaxomab is intricately linked to its trifunctional design. Upon administration, Catumaxomab binds simultaneously to:

• EpCAM-positive carcinomas: The EpCAM antigen is overexpressed on the surface of many epithelial cancer cells, making it an ideal target for tumor-specific recognition.
• CD3 on T-cells: By binding to the CD3 complex on T-lymphocytes, Catumaxomab effectively activates these crucial immune cells.
• Fcγ receptors on accessory cells: The Fc region of Catumaxomab engages with Fcγ receptors found on macrophages, NK cells, and dendritic cells, drawing these additional immune components into the anti-tumor fight.

This simultaneous binding creates an immunological synapse, bridging tumor cells with both T-cells and accessory immune cells. This close proximity facilitates direct cytotoxicity by activated T-cells and also triggers other immune mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The result is a highly localized and potent anti-tumor immune response, leading to the destruction of cancer cells. Furthermore, Catumaxomab can induce a sustained immune system modulation, leading to a long-lasting anti-tumor effect beyond the immediate drug presence.

Medical Uses

The primary medical use for which Catumaxomab was approved was the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer effective. Malignant ascites, a common complication in advanced cancers such as ovarian, gastric, and colorectal cancer, involves the pathological accumulation of fluid in the peritoneal cavity, causing significant discomfort and reduced quality of life.

By directly administering Catumaxomab into the peritoneal cavity, it could directly target the tumor cells lining the peritoneum, which are often the source of the malignant ascites. This localized delivery minimized systemic side effects while maximizing the therapeutic effect at the site of disease. Clinical trials demonstrated its efficacy in reducing ascites formation, alleviating symptoms, and improving the quality of life for these patients.

Dosage

Catumaxomab was typically administered via intraperitoneal (IP) infusion. The standard dosage regimen involved a series of four infusions, usually given over an 11-day period. The dose was escalated with each subsequent infusion to manage potential immune responses and maximize efficacy:

• Day 0: 10 µg
• Day 3: 20 µg
• Day 7: 50 µg
• Day 10: 150 µg

Each infusion was typically diluted in a suitable solution (e.g., physiological saline) and administered slowly over several hours. Due to its nature as an immunomodulatory agent and the potential for acute reactions, Catumaxomab treatment required careful monitoring in a hospital setting. Premedication with antihistamines, corticosteroids, and antipyretics was often recommended to mitigate infusion-related reactions.

Side Effects

As a potent immunotherapeutic, Catumaxomab was associated with immune-activating side effects. Common adverse events included infusion-related reactions such as fever, chills, nausea, vomiting, fatigue, headache, and abdominal pain, often managed with premedication. Gastrointestinal disturbances and transient hematological changes were also observed. More serious, though less frequent, side effects included Cytokine Release Syndrome (CRS), hypersensitivity reactions, and neurological events. Careful patient selection and monitoring were paramount due to potential significant immune-mediated effects.

Drug Interactions

Due to its immune system involvement, Catumaxomab could potentially interact with immunosuppressive agents like systemic corticosteroids, reducing its efficacy. Conversely, other immunotherapeutic agents might alter its effects or increase toxicity. Patients undergoing Catumaxomab treatment required a full medication history review. While specific, widely documented interactions are not extensively detailed, caution with other immune-modulating drugs was crucial, and healthcare providers assessed risk-benefit for combination therapies.

FAQ

• Is Catumaxomab still available for treatment? Catumaxomab (Removab®) was withdrawn from the market in 2017 due to commercial reasons, not safety concerns, making it generally unavailable for new treatments.
• What type of cancer did Catumaxomab treat? It was approved for the treatment of malignant ascites in patients with EpCAM-positive carcinomas, such as those originating from ovarian, gastric, or colorectal cancers.
• How was Catumaxomab administered? It was administered directly into the abdominal cavity via intraperitoneal infusion.
• What made Catumaxomab unique? Its unique trifunctional antibody structure allowed it to simultaneously bind to tumor cells, T-cells, and accessory immune cells, effectively bridging them to initiate a potent and localized anti-tumor immune response.

Products containing Catumaxomab are available through trusted online pharmacies. You can browse Catumaxomab-based medications at ShipperVIP or Medicenter.

Summary

Catumaxomab represented a significant innovation in cancer therapy as the first-in-class trifunctional antibody. Its ingenious design allowed it to orchestrate a targeted immune attack against EpCAM-positive tumor cells, particularly in the challenging context of malignant ascites. While no longer commercially available, its legacy as a pioneering immunotherapeutic agent continues to influence the development of next-generation bispecific and multi-specific antibodies. Its unique mechanism of bridging various immune cells to cancer cells provided valuable insights into harnessing the body's own defenses, paving the way for future advances in oncology and demonstrating the potential of sophisticated antibody engineering.